Clairfield International has been appointed as the transaction advisor to SDS Optic S.A. for the commercialization of inPROBE

January 3, 2023

On January 3, 2023, SDS Optic S.A., a company listed on NewConnect that is developing its proprietary inPROBE^® technology platform for real-time medical diagnostics of cancer and infectious diseases, as well as health monitoring, signed an advisory agreement with the renowned firm Clairfield International, headquartered in New York. Clairfield will be responsible, among other tasks, for identifying and selecting potential buyers and generating interest in the inPROBE^® technology platform.

The partner's activities within the cooperation will include, among other things, preparing necessary reports and establishing contacts with global companies in the healthcare sector, with a main focus on so-called big pharma and big medtech companies. In the next phase, Clairfield will support the Company in organizing the due diligence process, shaping the negotiation strategy, and final discussions related to the formation of the contract for the commercialization of the inPROBE^® technology platform. The agreement includes the option to scale it to other applications, licensing, or acquiring selected applications for the technology’s use.

"We are very pleased to be able to advise SDS Optic, a multi-award-winning company developing inPROBE^® – a groundbreaking diagnostic technology with applications, among others, in the oncology sector. SDS Optic has achieved a number of milestones toward commercialization, and their technology has the potential to become a breakthrough in both the cancer diagnostics sector and the development of innovative drugs, primarily due to its much greater sensitivity and effectiveness. We are excited to support the SDS Optic team in generating interest from potential partners and to collaboratively build the commercial success of the inPROBE^® technology," – says Crosby O'Hare, Founder and Managing Partner at Clairfield International..

According to the adopted schedule, the start of work is planned for February 1, 2023, divided into 3 stages:

• •development of a detailed strategy and action plan
• •preparation of presentation materials, a list of potential partners, and a path for acquiring them
• •marketing and promotion of the project among potential commercialization partners

"Clairfield International is a leading transactional advisor globally in its category, bringing vast knowledge and connections with the largest companies worldwide to our inPROBE^® technology commercialization process, thanks to its experience in medical technology and biotechnology. We have had a relationship with the Clairfield International team for over three years, so we know each other very well. We have had many fruitful meetings, both at the company headquarters and in New York. Through these, Clairfield has become very familiar with our groundbreaking technology, and together we were able to select the best moment to begin full collaboration. We are extremely pleased to have reached the point where we can confidently say this is the right moment to begin active efforts to find a partner for commercialization. Clairfield brings a vast network of contacts, knowledge, and experience in medical and pharmaceutical technology transactions, and their recent partnership agreement with Yamada Consulting Group, a leading transactional advisory firm in Japan and Southeast Asia, further increases our potential to secure a partner in multiple markets. It is worth highlighting that the best global corporations in endoscopic technology are based in Asia. We, on our part, declare full readiness and openness to ensure the process runs smoothly and leads to mutual success in the commercialization of inPROBE^® technology,” says Mateusz Sagan, COO of SDS Optic S.A.

"We are confident that we possess a wealth of knowledge and understanding of the inPROBE^® technology, its development stage, and that we are at the right moment to support the most attractive transaction possible for SDS Optic and its shareholders. We greatly value the regular contact and communication we have maintained with SDS Optic over the past three years. We are certain that Clairfield will be an excellent advisor and advocate for all the hard work that SDS Optic has done over the years to reach this important moment. We are proud to become part of this team," says Edward Grey, Managing Director at Clairfield.

Clairfield International is an international firm providing corporate finance services, primarily in mergers and acquisitions, to international corporations and financial investors. The advisor focuses on the mid-market segment, handling transactions with a value of up to EUR 500 million (enterprise value). The firm is ranked among the top twenty financial advisors globally and seventh in healthcare sector transactions, according to the Global Mid-Market M&A Review List compiled by Refinitiv. Clairfield employs approximately 300 specialists in 25 countries and has participated in over 700 transactions totaling EUR 25 billion over the last five years. In November 2022, Clairfield signed a strategic partnership agreement with Yamada Consulting Group, one of the largest and most renowned transaction advisory firms in Japan and Southeast Asia. As part of healthcare sector transactions, Clairfield is expanding its expertise in biotechnology, pharmaceuticals, medical devices and supplies, hospitals and clinics, as well as laboratory services and equipment. In biotechnology and medical device projects, Clairfield has particular experience in molecular diagnostics and therapeutics.